

## Product datasheet for TG318921

## **RPL22 Human shRNA Plasmid Kit (Locus ID 6146)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** RPL22 Human shRNA Plasmid Kit (Locus ID 6146)

Locus ID:

Synonyms: EAP; HBP15; HBP15/L22; L22

Vector: pGFP-V-RS (TR30007)

E. coli Selection: Kanamycin Mammalian Cell Puromycin

Selection:

Format: Retroviral plasmids

RPL22 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 6146). Components:

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.

NM 000983, NM 000983.1, NM 000983.2, NM 000983.3, BC058887, BC011829, BC020237, RefSeq:

BC032295, BC035566, BC066314, NM 000983.4

**UniProt ID:** P35268

**Summary:** Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and

a large 60S subunit. Together these subunits are composed of 4 RNA species and

approximately 80 structurally distinct proteins. This gene encodes a cytoplasmic ribosomal protein that is a component of the 60S subunit. The protein belongs to the L22E family of ribosomal proteins. Its initiating methionine residue is post-translationally removed. The protein can bind specifically to Epstein-Barr virus-encoded RNAs (EBERs) 1 and 2. The mouse protein has been shown to be capable of binding to heparin. Transcript variants utilizing alternative polyA signals exist. As is typical for genes encoding ribosomal proteins, there are

multiple processed pseudogenes of this gene dispersed through the genome. It was

previously thought that this gene mapped to 3q26 and that it was fused to the acute myeloid leukemia 1 (AML1) gene located at 21q22 in some therapy-related myelodysplastic syndrome patients with 3;21 translocations; however, these fusions actually involve a ribosomal protein L22 pseudogene located at 3q26, and this gene actually maps to 1p36.3-p36.2. [provided by

RefSeq, Jul 2008]



OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com





shRNA Design:

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>. If you need a special design or shRNA sequence, please utilize our <a href="mailto:custom shRNA service">custom shRNA service</a>.

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).